For example, miR-130 acts as a promoter of malignancy through the downregulation of PTEN expression in bladder cancer [91], invasive breast carcinoma [92], renal cell carcinoma [93], gastric cancer [94], gliomas [95], lung adenocarcinoma [96], and in colon adenocarcinoma [97]. The gene discussed is PTEN; the disease is urinary bladder cancer.